Iovance Biotherapeutics

Yahoo Finance • 4 months ago

3 Monster Biotech Stocks to Buy Before 2025

Many investors rightfully identify biotech stocks as being riskier than average, and those stocks certainly have a habit of earning their reputation. Still, there are a few up-and-coming biotechs that have revenue and a clear path to gener... Full story

Yahoo Finance • 7 months ago

Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting

Iovance Biotherapeutics, Inc. Lifileucel TIL Cell Therapy in Combination with Pembrolizumab Demonstrates Deep, Durable Responses in Frontline Advanced Melanoma Patients in IOV-COM-202 Clinical Study ASCO Oral Presentation to Highlight 65... Full story

Yahoo Finance • 7 months ago

Why Iovance Stock Is Down 18% Today

Iovance Biotherapeutics(NASDAQ: IOVA) shares are down to the tune of 18% today following Thursday evening's release of its first-quarter numbers. The sell-off clearly suggests investors didn't like everything they heard. The knee-jerk resp... Full story

Yahoo Finance • 8 months ago

Got $500? These Hot Growth Stocks Are Screaming Buys Right Now

They're often grouped together, but not all growth stocks are the same. Indeed, they're each dramatically different in terms of risk, potential, and longevity. One's not inherently as good as another. With that as the backdrop, here's a c... Full story

Yahoo Finance • 8 months ago

3 Millionaire-Maker Biotech Stocks

It's been a tough past three years for biotech stocks. Although the COVID-19 pandemic sparked bullish interest in the industry, this interest has waned since the contagion began winding down. Between late 2021 and now, the Nasdaq Biotechno... Full story

Yahoo Finance • 10 months ago

Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy?

Some investors are attracted to small biotech stocks because of their potential for explosive returns. It's not uncommon for these stocks to go parabolic after positive news is announced. That's exactly what happened to Iovance Biotherape... Full story

Yahoo Finance • 10 months ago

This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst

With shares of Iovance Biotherapeutics (NASDAQ: IOVA) soaring by 175% in the last three months, Wells Fargo analyst Yanan Zhu thinks they could still go as much as 47% higher. In fact, on Feb. 20, the analyst raised his price target for th... Full story

Yahoo Finance • 10 months ago

13 Best Short Squeeze Stocks To Buy Now

In this piece, we will take a look at the 13 best short squeeze stocks to buy now. If you want to skip our primer on short squeezing, and some of the greatest short squeezes in history, then you can take a look at the 5 Best Short Squeeze... Full story

Yahoo Finance • 10 months ago

Why Iovance Biotherapeutics Stock Is Skyrocketing Today

Shares of Iovance Biotherapeutics(NASDAQ: IOVA) had skyrocketed by 33.8% as of 10:39 a.m. ET Tuesday. The huge gain came after the company announced on Friday that the Food and Drug Administration (FDA) had granted accelerated approval for... Full story

Yahoo Finance • 10 months ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics, Inc. SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel... Full story

Yahoo Finance • 12 months ago

Iovance Stock Plunges as FDA Puts Hold on Lung Cancer Study After Patient Death

The FDA places a clinical hold on Iovance’s trial of a lung cancer therapy after the company reports a death potentially related to the treatment. Continue reading... Full story

Yahoo Finance • last year

A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street

It isn't over yet, but 2023 has given Wall Street a lot more to be excited about than 2022 did. Signs of a soft landing for the U.S. economy have pushed the S&P 500 index up nearly 20% this year. The benchmark index is up sharply this yea... Full story

Yahoo Finance • last year

Why Iovance Biotherapeutics Stock Is Jumping Today

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were jumping 10.9% higher as of 11:49 a.m. ET on Monday. The nice gain came after Goldman Sachs initiated coverage on Iovance stock with a buy recommendation. Investors no doubt liked Goldma... Full story

Yahoo Finance • last year

Catherine Wood Adjusts Portfolio, Trims Tesla Stake by 1.33%

ARK Investment Management's Latest 13F Filing Highlights Key Stock Movements Renowned for her focus on disruptive innovation, Catherine Wood (Trades, Portfolio), the founder and CEO of ARK Investment Management, has made notable changes t... Full story

Yahoo Finance • last year

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates

FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act Action (PDUFA) Date of February 24, 2023 Positive Regulatory Feedback Supports Lifileucel Regulato... Full story

Yahoo Finance • last year

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress

SAN CARLOS, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies... Full story

Yahoo Finance • last year

Investor Alert: Abbott Cooper PLLC Announces Investigation into Iovance Biotherapeutics, Inc.; Urges Iovance Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”) on behalf of the Company’s investors to determine whether Iovance’s board of... Full story

Yahoo Finance • last year

Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies... Full story

Yahoo Finance • last year

U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma

Priority Review Continues with Successful Facility Inspections Completed, no Major Review Issues FDA Extends PDUFA Date to February 24, 2024 on Resource Constraints and Agrees to Work with Iovance to Expedite Remaining Review SAN CARLOS,... Full story

Yahoo Finance • last year

Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering

SAN CARLOS, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies... Full story